NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,445.26 +238.13 (+1.31%) CRUDE OIL
79.17 +0.22 (+0.28%) GOLD FUTURES
2,311.70 +2.10 (+0.09%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,376.16 +1,709.05 (+3.74%)
Phio Pharmaceuticals Corp. (PHIO)
After hours:
| Previous close | 0.7585 |
| Open | 0.7490 |
| Bid | 0.7557 x 100 |
| Ask | 0.8215 x 100 |
| Day's range | 0.7301 - 0.8299 |
| 52-week range | 0.5000 - 6.8500 |
| Volume | |
| Avg. volume | 418,372 |
| Market cap | 3.562M |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.2000 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
GlobeNewswirePhio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
-Phio’s lead clinical product candidate, PH-762, is the focus of dermatological poster presentationMARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead product candidate, PH-762, an INTASYL compound. PH-762 is currently being st
- GlobeNewswire
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting n
- GlobeNewswire
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Phio’s lead clinical product candidate, PH-762, is the subject of three new dermatological postersMARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical candidate, PH-762, an INTASYL compound. The data will be presented i
